BeiGene Opens U.S. Biologics Manufacturing and R&D Facility in Hopewell

On Jul 23, 2024

Global oncology company BeiGene, Ltd. today opened its flagship US facility in Hopewell. Located at the Princeton West Innovation Campus, the facility houses state-of-the-art biologics manufacturing capabilities and a clinical research and development center.

This $800 million investment by the company is the culmination of a three-year project to expand the BeiGene’s integrated manufacturing and research and development footprint in the U.S. It is expected to create hundreds of skilled high-tech jobs at the site by the end of 2025.

The site features approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing capacity with space to expand over time, allowing flexibility as BeiGene’s pipeline continues to mature. The company already has more than 30 molecules at clinical or commercial stage.

The facility adds to BeiGene’s late-stage research and clinical development capabilities, which have enabled the company’s fast rise to global oncology leadership.

“BeiGene has experienced unprecedented global growth, and the addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities that will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance quality medicines faster for patients,” said John V. Oyler, co-founder, chairman and CEO of BeiGene. “We are proud to be a part of New Jersey’s biopharmaceutical community that is rich in research and development and manufacturing talent. We look forward to deepening our relationships with key regional research institutions as we advance our robust pipeline of next-generation hematology and solid tumor medicines and continue to emerge as a leading global oncology innovator.”

“I am thrilled by BeiGene’s contribution to our state’s thriving biopharmaceutical sector,” said Gov. Phil Murphy. “The opening of BeiGene’s flagship campus underscores our commitment to fostering innovation and creating high-tech jobs in the Garden State. We look forward to the positive impact BeiGene will have on our economy and the advancements they will bring to cancer treatment. This significant investment highlights New Jersey’s role as a global leader in pharmaceutical manufacturing, research and development.”

“I am excited to welcome BeiGene to Hopewell Township. BeiGene’s new cutting-edge pharmaceutical facility represents a significant investment in our community’s future. The life-saving medicines made right here in Hopewell will not only enhance global cancer treatment, but will also create good-paying, high-tech jobs and strengthen our local economy,” said Hopewell Township Mayor Courtney Peters-Manning. “We look forward to the company’s continued success in Hopewell Township.”

To access more business news, visit NJB News Now.

Related Articles: